GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fulcrum Therapeutics Inc (NAS:FULC) » Definitions » PB Ratio

Fulcrum Therapeutics (Fulcrum Therapeutics) PB Ratio : 1.88 (As of Apr. 27, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Fulcrum Therapeutics PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-04-27), Fulcrum Therapeutics's share price is $7.14. Fulcrum Therapeutics's Book Value per Share for the quarter that ended in Dec. 2023 was $3.80. Hence, Fulcrum Therapeutics's PB Ratio of today is 1.88.

The historical rank and industry rank for Fulcrum Therapeutics's PB Ratio or its related term are showing as below:

FULC' s PB Ratio Range Over the Past 10 Years
Min: 0.5   Med: 2.28   Max: 9.08
Current: 1.88

During the past 7 years, Fulcrum Therapeutics's highest PB Ratio was 9.08. The lowest was 0.50. And the median was 2.28.

FULC's PB Ratio is ranked better than
59.66% of 1309 companies
in the Biotechnology industry
Industry Median: 2.38 vs FULC: 1.88

During the past 12 months, Fulcrum Therapeutics's average Book Value Per Share Growth Rate was -0.50% per year. During the past 3 years, the average Book Value Per Share Growth Rate was 3.70% per year.

During the past 7 years, the highest 3-Year average Book Value Per Share Growth Rate of Fulcrum Therapeutics was 3.70% per year. The lowest was -0.20% per year. And the median was 1.75% per year.

Back to Basics: PB Ratio


Fulcrum Therapeutics PB Ratio Historical Data

The historical data trend for Fulcrum Therapeutics's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fulcrum Therapeutics PB Ratio Chart

Fulcrum Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Get a 7-Day Free Trial 4.33 3.44 3.40 1.91 1.78

Fulcrum Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.91 0.59 0.74 1.07 1.78

Competitive Comparison of Fulcrum Therapeutics's PB Ratio

For the Biotechnology subindustry, Fulcrum Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fulcrum Therapeutics's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fulcrum Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Fulcrum Therapeutics's PB Ratio falls into.



Fulcrum Therapeutics PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Fulcrum Therapeutics's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2023)
=7.14/3.799
=1.88

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Fulcrum Therapeutics  (NAS:FULC) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Fulcrum Therapeutics PB Ratio Related Terms

Thank you for viewing the detailed overview of Fulcrum Therapeutics's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Fulcrum Therapeutics (Fulcrum Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
26 Landsdowne Street, Cambridge, MA, USA, 02139
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. The company's proprietary product engine, FulcrumSeek, identifies drug targets that can modulate gene expression to treat the known root cause of gene mis-expression.
Executives
Alan A Musso officer: Chief Financial Officer FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Alex Sapir director, officer: See Remarks C/O DOVA PHARMACEUTICALS, INC., 240 LEIGH FARM ROAD, SUITE 245, DURHAM NC 27707
Greg Tourangeau officer: Controller C/O FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Ra Capital Healthcare Fund Lp 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Robert J Gould director, officer: President & CEO C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
Santiago Arroyo officer: Chief Medical Officer C/O MOMENTA PHARMACEUTICALS, INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Rajeev M. Shah 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Management, L.p. 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Peter Kolchinsky 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Hayes Melvin H. Iii officer: Chief Operating Officer FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Esther Rajavelu officer: Chief Financial Officer 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Sonja Banks director C/O FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Bryan Stuart officer: Chief Operating Officer C/O CIVITAS THERAPEUTICS, INC., 190 EVERETT AVENUE, CHELSEA MA 02150
Christopher Moxham officer: Chief Scientific Officer 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Peter G. Thomson officer: VP Finance & Accounting C/O FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139

Fulcrum Therapeutics (Fulcrum Therapeutics) Headlines

From GuruFocus